Clinical Features and Efficacy of Benralizumab in Patients with Blood Eosinophil Count Between 300 and 450 Cells/mm3: A Post Hoc Analysis from the ANANKE Study

Editorial Material Allergy

Effectiveness of Benralizumab in Severe Eosinophilic Asthma Under Conditions of Routine Clinical Practice

J. C. Miralles Lopez et al.

JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY (2022)

Review Medicine, General & Internal

Biologic Therapies for Severe Asthma

Guy G. Brusselle et al.

Summary: Biologic therapies may be necessary to reduce the disease burden and risks for severe asthma patients. This review discusses the mechanisms, efficacy, and safety of biologics for severe asthma.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Article Critical Care Medicine

Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study

Andrew Menzies-Gow et al.

Summary: This study evaluated the impact of reducing oral corticosteroids after initiating benralizumab treatment on patients with severe eosinophilic asthma. The study found that with a personalized dosage reduction algorithm, most patients were able to successfully reduce or eliminate the use of oral corticosteroids, and the treatment was safe.

LANCET RESPIRATORY MEDICINE (2022)

添加到收藏夹

Article Respiratory System

Novel mechanisms of action contributing to benralizumab's potent anti-eosinophilic activity

Rania Dagher et al.

Summary: Benralizumab, a humanised monoclonal antibody, shows potent anti-eosinophilic activity through induction of eosinophil apoptosis and phagocytosis by macrophages. The mechanism involves NK cells, macrophage-derived TNF, and activation of Caspase-3/7 and cytochrome c. The afucosylation of benralizumab enhances its potency for these mechanisms.

EUROPEAN RESPIRATORY JOURNAL (2022)

添加到收藏夹

Article Respiratory System

ChAracterization of ItaliaN severe uncontrolled Asthmatic patieNts Key features when receiving Benralizumab in a real-life setting: the observational rEtrospective ANANKE study

Francesco Menzella et al.

Summary: This study examined the baseline characteristics and therapy effectiveness of patients with severe eosinophilic asthma (SEA) treated with benralizumab in a real-world setting. The results showed that benralizumab treatment significantly reduced exacerbations and the use of oral corticosteroids, and improved lung function and asthma control.

RESPIRATORY RESEARCH (2022)

添加到收藏夹

Article Respiratory System

High eosinophil counts predict decline in FEV1: results from the CanCOLD study

Wan C. Tan et al.

Summary: This study found that older adults with a higher blood eosinophil count have a faster decline in lung function and are associated with undetected structural airway abnormalities.

EUROPEAN RESPIRATORY JOURNAL (2021)

添加到收藏夹

Article Allergy

Allergen immunotherapy: The growing role of observational and randomized trial Real-World Evidence

Giovanni Paoletti et al.

Summary: Establishing more AIT registries that collect data in a cohesive way using standardized protocols is crucial for providing easily shareable real-world data, ultimately promoting evidence-based research and quality improvement in study design and clinical decision-making.

ALLERGY (2021)

添加到收藏夹

Article Pharmacology & Pharmacy

Effectiveness of Benralizumab in Improving the Quality of Life of Severe Eosinophilic Asthmatic Patients: Our Real-Life Experience

Giulia Scioscia et al.

Summary: Adding benralizumab treatment in patients with severe eosinophilic asthma significantly reduces nocturnal and diurnal symptoms, allows cessation of oral corticosteroid use, and leads to a notable improvement in patients' quality of life perception.

FRONTIERS IN PHARMACOLOGY (2021)

添加到收藏夹

Article Allergy

Therapeutic Effects of Benralizumab Assessed in Patients with Severe Eosinophilic Asthma: Real-Life Evaluation Correlated with Allergic and Non-Allergic Phenotype Expression

Corrado Pelaia et al.

Summary: This multicenter observational investigation evaluated the therapeutic effects of benralizumab in patients with severe uncontrolled eosinophilic asthma, showing significant improvement in symptoms and quality of life after 6 months of treatment.

JOURNAL OF ASTHMA AND ALLERGY (2021)

添加到收藏夹

Article Respiratory System

Real world effectiveness of benralizumab on respiratory function and asthma control

Francesco Menzella et al.

Summary: This retrospective real-life observational study evaluated the effect of add-on benralizumab on lung function, exacerbation rate, oral corticosteroids reduction, and asthma control questionnaire score after 52-weeks. The results showed significant improvement in respiratory function, reduction in exacerbations, and better asthma control with benralizumab treatment. Overall, benralizumab proved to be a reliable and safe therapeutic option for severe eosinophilic asthma.

MULTIDISCIPLINARY RESPIRATORY MEDICINE (2021)

添加到收藏夹

Article Critical Care Medicine

Eosinophilic and Noneosinophilic Asthma An Expert Consensus Framework to Characterize Phenotypes in a Global Real-Life Severe Asthma Cohort

Liam G. Heaney et al.

Summary: By analyzing patients with severe asthma from 11 countries globally, this study found the prevalence of eosinophilic and noneosinophilic asthma phenotypes, as well as the differences in characteristics between the two phenotypes, providing important insights for personalized treatment.

CHEST (2021)

添加到收藏夹

Article Respiratory System

Patient characteristics, biomarkers and exacerbation risk in severe, uncontrolled asthma

Monica Kraft et al.

Summary: This study identified clinical characteristics and biomarkers associated with elevated exacerbation risk in severe, uncontrolled asthma patients. Factors such as exacerbation history, maintenance corticosteroid use, nasal polyposis, Asian race, geographic region, and elevated blood eosinophil counts and F-ENO concentrations were found to be correlated with increased exacerbation risk when combined or persistently achieving type 2 inflammation criteria.

EUROPEAN RESPIRATORY JOURNAL (2021)

添加到收藏夹

Article Allergy

Benralizumab Effectiveness in Severe Eosinophilic Asthma with and without Chronic Rhinosinusitis with Nasal Polyps: A Real-World Multicenter Study

Santi Nolasco et al.

Summary: Real-world data suggests that benralizumab is a valid add-on therapeutic option for patients with severe eosinophilic asthma, especially those with comorbid chronic rhinosinusitis with nasal polyps. Treatment with benralizumab led to significant improvements in asthma exacerbations, lung function, and blood cell counts, indicating its potential efficacy in managing late-onset severe asthma.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2021)

添加到收藏夹

Article Allergy

Integrated Safety and Efficacy Among Patients Receiving Benralizumab for Up to 5 Years

Stephanie Korn et al.

Summary: The study evaluated the long-term safety and tolerability of benralizumab in adults with severe, uncontrolled eosinophilic asthma over a period of up to 5 years. The results showed that benralizumab was safe and well tolerated, with no new safety signals observed, and a significant reduction in exacerbations similar to previous studies.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2021)

添加到收藏夹

Article Allergy